首页> 美国卫生研究院文献>Diagnostic Pathology >Expression of ck-19 galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis
【2h】

Expression of ck-19 galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis

机译:ck-19galectin-3和hbme-1在甲状腺病变中的表达:系统评价和诊断性荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTo distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the differentiation of malignant and benign thyroid lesions.
机译:背景技术由于术前应用的细针穿刺活检方法有一定的局限性,因此常常需要区分甲状腺的恶性病变和良性病变。为了提高诊断准确性,已经研究了使用免疫细胞化学和免疫组织化学技术的标记物,主要是细胞角蛋白19(CK-19),半乳凝素3(Gal-3)和赫克托·巴蒂福拉间皮1(HBME-1)。但是,目前的结果仍存在争议。本文的目的是建立CK-19,Gal-3和HBME-1标记物的诊断准确性,以及它们在恶性和良性甲状腺病变鉴别中的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号